发明名称 Inhibition of choroidal neovascularization
摘要 Methods of treatment of diseases that include or are characterized by inappropriate or pathological neovascularization are disclosed. These diseases include diseases of the eye, such as diabetic retinopathy, retinopathy of prematurity, and choroidal neovascularization which can occur in age-related macular degeneration (AMD). Disclosed methods include administering agents that cause directly or indirectly upregulation of the ABCA1 transporter protein in macrophages. These agents include, without limitation, LXR agonists. In some embodiments, inhibitors of CETP expression or activity can also be effective. Administration routes can include, without limitation, intraocular, periocular, or systemic administration.
申请公布号 US9121019(B2) 申请公布日期 2015.09.01
申请号 US201313918453 申请日期 2013.06.14
申请人 Washington University 发明人 Apte Rajendra S.
分类号 C12N15/113;A61K31/18;A61K31/195;A61K31/421;A61K31/4706;A61K31/575;A61K31/58;A61K9/00;A61K38/17 主分类号 C12N15/113
代理机构 Zackson Law LLC 代理人 Zackson Law LLC ;Zackson Saul L.
主权项 1. A method of treating an ocular disease characterized by choroidal neovascularization (CNV), comprising administering to a subject in need thereof a therapeutically effective amount of an inhibitor of miR33, wherein the inhibitor of miR33 is a single-stranded RNA which inhibits miR33.
地址 St. Louis MO US